Form 4: Cardiff Oncology Director Gary W. Pace Reports Stock Option Grant
SEC Form 4 Filing
Director Gary W. Pace of Cardiff Oncology, Inc. reports the acquisition of 29,700 stock options on June 27, 2024.
Summary
- Gary W. Pace, a director of Cardiff Oncology, Inc., filed a Form 4 with the SEC.
- The filing reports a transaction that occurred on June 27, 2024.
- Pace acquired 29,700 stock options with an exercise price of $2.33.
- The options become exercisable on June 27, 2025, and expire on June 27, 2034.
- Following the reported transaction, Pace directly owns 146,974 shares of Cardiff Oncology, Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which doesn't inherently indicate positive or negative sentiment.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates changes in the holdings of a director at Cardiff Oncology, which is common for publicly traded companies.
Stakeholder Impact
- Shareholders may view the granting of stock options to a director as a way to align management's interests with their own.
Key Dates
| Date | Description |
|---|---|
| 06/27/2024 | Date of stock options transaction |
| 06/27/2025 | Date stock options become exercisable |
| 06/27/2034 | Expiration date of stock options |
| 07/01/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.